Literature DB >> 18385248

Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Thomas W Geisbert1, Kathleen M Daddario-DiCaprio, Kinola J N Williams, Joan B Geisbert, Anders Leung, Friederike Feldmann, Lisa E Hensley, Heinz Feldmann, Steven M Jones.   

Abstract

Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus. Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after exposure to SEBOV. All four animals survived SEBOV challenge, while a control animal that received a nonspecific vector developed fulminant SEBOV hemorrhagic fever and succumbed. This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses.

Entities:  

Mesh:

Year:  2008        PMID: 18385248      PMCID: PMC2395203          DOI: 10.1128/JVI.00456-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

Authors:  Michael Garbutt; Ryan Liebscher; Victoria Wahl-Jensen; Steven Jones; Peggy Möller; Ralf Wagner; Viktor Volchkov; Hans-Dieter Klenk; Heinz Feldmann; Ute Ströher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Ebola outbreak in Uganda "atypical", say experts.

Authors:  Zoe Alsop
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

3.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

4.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

5.  Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys.

Authors:  D S Ellis; E T Bowen; D I Simpson; S Stamford
Journal:  Br J Exp Pathol       Date:  1978-12

6.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

7.  Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.

Authors:  Kathleen M Daddario-DiCaprio; Thomas W Geisbert; Ute Ströher; Joan B Geisbert; Allen Grolla; Elizabeth A Fritz; Lisa Fernando; Elliott Kagan; Peter B Jahrling; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

8.  VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Authors:  Sven Enterlein; Kelly L Warfield; Dana L Swenson; David A Stein; Jeffery L Smith; C Scott Gamble; Andrew D Kroeker; Patrick L Iversen; Sina Bavari; Elke Mühlberger
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

Authors:  M Hevey; D Negley; P Pushko; J Smith; A Schmaljohn
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

10.  Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.

Authors:  Thomas W Geisbert; Lisa E Hensley; Elliott Kagan; Erik Zhaoying Yu; Joan B Geisbert; Kathleen Daddario-DiCaprio; Elizabeth A Fritz; Peter B Jahrling; Kevin McClintock; Janet R Phelps; Amy C H Lee; Adam Judge; Lloyd B Jeffs; Ian MacLachlan
Journal:  J Infect Dis       Date:  2006-05-10       Impact factor: 5.226

View more
  78 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Dana L Swenson; Kelly S Donner; Sean A Van Tongeren; Nicole L Garza; Lian Dong; Dan V Mourich; Stacy Crumley; Donald K Nichols; Patrick L Iversen; Sina Bavari
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

4.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 5.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

6.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

7.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Authors:  Lauren M Smith; Lisa E Hensley; Thomas W Geisbert; Joshua Johnson; Andrea Stossel; Anna Honko; Judy Y Yen; Joan Geisbert; Jason Paragas; Elizabeth Fritz; Gene Olinger; Howard A Young; Kathleen H Rubins; Christopher L Karp
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.